

Frequently Asked Questions

The American Academy of Orthopaedic Surgeons (AAOS) Musculoskeletal Tumor (MsT) Registry Pilot Program FAQs

In December 2018, the AAOS Board of Directors and its Registry Oversight Committee (ROC), in a partnership with the [Musculoskeletal Tumor Society \(MSTS\)](#), launched a year-long Registry pilot project for data covering tumor procedures. The effort involves six pilot sites at major U.S. academic centers.

1) What is the MsT Registry Pilot Program?

The Musculoskeletal Tumor Registry is the third subspecialty registry to be incorporated into the AAOS family of registries. It is a feasibility pilot to assess the scope, scale, and structure needed to support a broader roll-out. Its initial focus is on tracking function, complications, and outcomes in patients treated for a bone or soft tissue sarcoma. Reports from this pilot will go to the AAOS Registry Oversight Committee (ROC) for review and strategic feedback. The expectation is that this pilot will provide learnings about a diagnosis-based registry with the intent to expand and allow other sites to join.

2) What data elements will be collected?

Data elements will include patient demographics, patient baseline and examination, tumor baseline, treatment and post-treatment, and surgery detail along with postoperative data (oncologic failure, surgery complication, vital status) and patient-reported outcomes (PROs) as conveyed in applicable instruments.


3) Is there a more in-depth description of the data being collected?

Description and details are available for [data specs](#) and the [data dictionary](#).

4) What organizations are participating in the pilot program?

This year-long effort involves six pilot sites at major U.S. academic centers. Listed below are the sites and the key surgeon lead at each:

- Cleveland Clinic Foundation - Nathan Mesko, MD; Luke Nystrom, MD
- Dartmouth-Hitchcock Medical Center - Eric Henderson, MD
- Johns Hopkins Medicine - Adam Levin, MD
- Ohio State University-The James Cancer Hospital - Joel Mayerson, MD
- Stanford Health Care- Stanford Hospital - Robert J. Steffner, MD
- University of Iowa Hospital and Clinics - Benjamin Miller, MD, MS



Frequently Asked Questions

5) **What is a bone tumor?**

Most bone tumors are benign (not cancerous or life-threatening) and, in most cases, will not spread to other parts of the body. Depending upon the type of tumor, treatment options are wide-ranging—from simple observation to surgery to remove the tumor.

Some bone tumors are malignant (cancerous bone tumors that could metastasize) and can cause cancer cells to spread throughout the body. In almost all cases, treatment for malignant tumors involves a combination of chemotherapy, radiation, and surgery.¹

6) **I would like to become involved in this pilot. How do I get started?**

We have currently filled all slots for the pilot program. Organizations interested in participating in the MsT Registry after the pilot assessment can [sign up here](#) to be contacted when more information becomes available.

To learn more, please contact a Registry Engagement Associate
(847) 292-0530 | RegistryInfo@aaos.org
or visit www.aaos.org/registries

1. www.orthoinfo.org